Fairmount Santrol Holdings Inc. (NYSE:FMSA) recorded a trading volume of 3.67 million shares, below its 90-day volume average of 6.7 million shares. The stock approached $4.8 with a change of -0.21%.Fairmount Santrol Holdings Inc. (FMSA) Analyst Opinion
Fairmount Santrol Holdings Inc. has a consensus outperform rating from 17 Wall Street analysts, and the number of shares currently sold short amount to at least 19.68% of shares outstanding. The stock spiked 57.89% last month and is down -59.29 this year. Wall Street is only getting more bullish on the stock, with 11 of analysts who cover FMSA having a buy-equivalent rating. Analysts have placed a $5.34 price target on Fairmount Santrol Holdings Inc., suggesting a 11.25% gain from recent close. It’s currently trading about -63.41% below its 52-week high.
Fairmount Santrol Holdings Inc. (FMSA) surprised the stock market in its last reported earnings when it earned $0.08 a piece versus the consensus-estimated $0.04. Its revenue totaled $231.28 million up 34.01% from the previous quarter.Fairmount Santrol Holdings Inc. (NYSE:FMSA) Intraday View
This stock (FMSA) is ahead of its 52-week low with 94.73%. Its last month’s stock price volatility remained 5.33% which for the week stands at 8.89%. The share price has moved forward from its 20 days moving average, trading at a distance of 12.93% and stays 42.21% away from its 50 days moving average. Over the last five days, shares have faced -2.83% losses and now is down -24.7% since hitting its 200-day moving average of $4.35. Fairmount Santrol Holdings Inc. (FMSA) has made its way to a 12-month decline of -50.72%.
Turning to Cellectar Biosciences, Inc. (NASDAQ:CLRB), its shares were trading at $1.79 a retreat of $-0.01, on the trading floor. The stock, after opening at $1.91, touched a high of $1.92 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1. Cellectar Biosciences, Inc. has 1 buy ratings, 0 holds and 0 sells even after the stock tumbled -41.69% from its high of $3.07 to a $24.63 million market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 1 to 1 during a month. Analysts set a 12-month price target of $3.1 a share. The target implies a 73.18% spike from where the shares are currently trading. Also, the current price highlights a discount of 73.18% to analysts’ high consensus price target.Cellectar Biosciences, Inc. (NASDAQ:CLRB) Intraday Trading
The counter witnessed a trading volume of 0.49 million shares versus an average volume of 0.24 million shares during last trading session. Its last month’s stock price volatility remained 6.8% which for the week approaches 6.77%. The lowest price the stock reached in the last trading day was $1.72 and compares with the $1.12 52-week low. The stock recovered 59.82% since its low point and has performed 46.72% year-to-date.